BridgeBio Pharma (BBIO) Change in Cash (2018 - 2026)

BridgeBio Pharma has disclosed Change in Cash across 9 years of filings, most recently posting $309.9 million for Q1 2026.

• Change in Cash for Q1 2026 came in at $309.9 million, up 320.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $339.3 million (up 420.0% YoY), and the FY2025 annual result was -$111.1 million, down 138.51% from the prior year.
• Change in Cash came in at $309.9 million for Q1 2026 at BridgeBio Pharma, up from -$73.0 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $309.9 million in Q1 2026 to a low of -$141.6 million in Q3 2024.
• The 5-year median for Change in Cash is $13.1 million (2022), against an average of $28.6 million.
• Across the five-year window, Change in Cash jumped 1418.35% in 2023 and plunged 269.76% in 2025, its largest moves.
• BridgeBio Pharma's Change in Cash stood at -$68.9 million in 2022, then tumbled by 87.82% to -$129.4 million in 2023, then jumped by 312.79% to $275.4 million in 2024, then slumped by 126.49% to -$73.0 million in 2025, then soared by 524.75% to $309.9 million in 2026.
• The last three Change in Cash figures came in at $309.9 million (Q1 2026), -$73.0 million (Q4 2025), and -$106.0 million (Q3 2025), per Business Quant data.